Search research articles
Contact Us
Filters
Showing results (71-80 of 234) with videos related to
Page
of 24
Sort By:
The Prostate
|
November 7, 2017
Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer
Heather H Cheng, Melissa Plets, Hongli Li, et al.
Prostate Cancer and Prostatic Diseases
|
February 15, 2020
Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer
Risa L Wong, Mai T Duong, Catherine M Tangen, et al.
Journal of the National Cancer Institute
|
March 8, 2020
Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T
Ravi A Madan, Emmanuel S Antonarakis, Charles G Drake, et al.
Advances in Urology
|
January 3, 2014
Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer
Franklin C Lee, William Harris, Heather H Cheng, et al.
Urology
|
May 5, 2011
Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer
Evan Y Yu, Christophe Massard, Mitchell E Gross, et al.
The Prostate
|
March 14, 2019
Clinical determinants for successful circulating tumor DNA analysis in prostate cancer
Michael T Schweizer, Roman Gulati, Mallory Beightol, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 19, 2009
Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer
Evan Y Yu, George Wilding, Edwin Posadas, et al.
Clinical Genitourinary Cancer
|
December 24, 2013
Nonresponse to neoadjuvant chemotherapy for muscle-invasive urothelial cell carcinoma of the bladder
Matthew Mossanen, Franklin Lee, Heather Cheng, et al.
Plos One
|
September 30, 2020
Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer
Alexander S Carlson, Rigo I Acevedo, Daniel M Lim, et al.
The Canadian Journal of Urology
|
April 20, 2024
Optimizing outcomes in men with prostate cancer: the cardiovascular event lowering (CaELo) pathways
David E Crawford, David Albala, Marc B Garnick, et al.
Page
of 24
Search research articles
Search
Showing results (71-80 of 234) with videos related to
Sort By:
Page
of 24
The Prostate
|
November 7, 2017
Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer
Heather H Cheng, Melissa Plets, Hongli Li, et al.
Prostate Cancer and Prostatic Diseases
|
February 15, 2020
Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer
Risa L Wong, Mai T Duong, Catherine M Tangen, et al.
Journal of the National Cancer Institute
|
March 8, 2020
Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T
Ravi A Madan, Emmanuel S Antonarakis, Charles G Drake, et al.
Advances in Urology
|
January 3, 2014
Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer
Franklin C Lee, William Harris, Heather H Cheng, et al.
Urology
|
May 5, 2011
Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer
Evan Y Yu, Christophe Massard, Mitchell E Gross, et al.
The Prostate
|
March 14, 2019
Clinical determinants for successful circulating tumor DNA analysis in prostate cancer
Michael T Schweizer, Roman Gulati, Mallory Beightol, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 19, 2009
Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer
Evan Y Yu, George Wilding, Edwin Posadas, et al.
Clinical Genitourinary Cancer
|
December 24, 2013
Nonresponse to neoadjuvant chemotherapy for muscle-invasive urothelial cell carcinoma of the bladder
Matthew Mossanen, Franklin Lee, Heather Cheng, et al.
Plos One
|
September 30, 2020
Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer
Alexander S Carlson, Rigo I Acevedo, Daniel M Lim, et al.
The Canadian Journal of Urology
|
April 20, 2024
Optimizing outcomes in men with prostate cancer: the cardiovascular event lowering (CaELo) pathways
David E Crawford, David Albala, Marc B Garnick, et al.
Page
of 24